Gefarnate

Gefarnate

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A02BX07 (WHO)
Identifiers
IUPAC name (2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
CAS Number	51-77-4^Y
PubChem CID	5282182
ChemSpider	4445377^N
UNII	1ISE2Y6ULA
KEGG	D01529^Y
ChEMBL	ChEMBL2105085^N
CompTox Dashboard (EPA)	DTXSID0048636
ECHA InfoCard	100.000.111
Chemical and physical data
Formula	C27H44O2
Molar mass	400.647 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(C)/CCC=C(C)C
InChI InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+^N Key:ZPACYDRSPFRDHO-ROBAGEODSA-N^N
^NY (what is this?)  (verify)

Gefarnate is a drug used for the treatment of gastric ulcers.[1]

It also has been proposed for use in the treatment of dry eye syndrome.[2][3]

References

1. Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
2. Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. doi:10.1358/dnp.2008.21.3.1203413. PMID 18560615.
3. Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.^[permanent dead link‍]